Calyxo has 6 close competitors: BioLinq, Egenesis, Kriya Therapeutics.
Sector, valuation and status for each competitor.
company profile›
competitor›
competitor›
competitor›A private valuation and a public market cap share one column; each row names its basis and date.
CalyxoBioLinqEgenesisAbridgeLet AI run your outreach.
Calyxo competes with 6 companies here: BioLinq, Egenesis, Kriya Therapeutics, Redcliffe Lifetech, Abridge, Alloy Therapeutics.
Calyxo was last valued at $684.6M (Apr 2026). That price was agreed in one transaction and holds until the next round. A listed competitor is repriced every trading session.
No. Calyxo is a private company; its shares do not trade on a public exchange.
The last valuation is $684.6M.
Lead investors for each round are in the funding timeline.
The closest medical devices peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
